TrialCompass TCL
Back to results
Phase 2RecruitingPriority 2 · High priorityNCT04930653

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is studying Extracorporeal Photopheresis, Mogamulizumab, and other medications for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 3 US locations.

Who can join (key eligibility)

  • Age 18 Years or older
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Extracorporeal Photopheresis (PROCEDURE): Undergo ECP | Mogamulizumab (BIOLOGICAL): Given IV | Quality-of-Life Assessment (OTHER): Ancillary studies | Questionnaire Administration (OTHER): Ancillary studies

Drugs / treatments
Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment, Questionnaire Administration
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

NCT04930653

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This Phase 2 trial is studying Extracorporeal Photopheresis, Mogamulizumab, and other medications for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 3 US locations.

Who can join

  • Age 18 Years or older
  • Must be well enough for treatment (adequate performance status)

What's being tested

Extracorporeal Photopheresis (PROCEDURE): Undergo ECP | Mogamulizumab (BIOLOGICAL): Given IV | Quality-of-Life Assessment (OTHER): Ancillary studies | Questionnaire Administration (OTHER): Ancillary studies

Drugs / treatments: Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment, Questionnaire Administration

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 34 patients

Primary endpoint: Overall response rate (ORR); Incidence of adverse events

Ages: 18 Years to —

Start date: 2022-10-19 | Est. completion: 2028-06-15

Locations

3 US sites · 3 total

Arizona, California, Georgia

Contact

—

Sponsor: City of Hope Medical Center (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT04930653

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.